Pharmacodynamics of the Antiarrhythmic Disopyramide in Healthy Humans: Correlation of the Kinetics of the Drug and Its Effects

Overview

Journal J Pharmacokinet Biopharm

Specialty Pharmacology

Date 1976 Jun 1

PMID 978390

Citations 11

Authors

P H Hinderling

E R GARRETT

Affiliations

Soon will be listed here.

Citing Articles

Therapeutic drug monitoring of antiarrhythmic drugs.

Jurgens G, Graudal N, Kampmann J Clin Pharmacokinet. 2003; 42(7):647-63.

PMID: 12844326 DOI: 10.2165/00003088-200342070-00004.

Quantitative analysis of the disopyramide concentration-effect relationship.

Whiting B, Holford N, Sheiner L Br J Clin Pharmacol. 1980; 9(1):67-75.

PMID: 7356895 PMC: 1429920. DOI: 10.1111/j.1365-2125.1980.tb04799.x.

[The effect of disopyramide of left ventricular function: an echocardiographic study of the extent and time course (author's transl)].

Angermann C, Autenrieth G Klin Wochenschr. 1981; 59(14):803-11.

PMID: 7265814 DOI: 10.1007/BF01724687.

Pharmacokinetics and pharmacodynamics of the antiarrhythmic compound MD750819 in dogs with experimentally induced arrhythmias.

Dow J, Laquais B, Pourrias B, Benedetti M J Pharmacokinet Biopharm. 1982; 10(3):283-96.

PMID: 7175700 DOI: 10.1007/BF01059262.

Therapeutic drug monitoring of antiarrhythmic agents.

Brown J, SHAND D Clin Pharmacokinet. 1982; 7(2):125-48.

PMID: 7039925 DOI: 10.2165/00003088-198207020-00003.

References

Granier J . [A new antiarrhythmic agent: disopyramide]. Presse Med (1893). 1968; 76(32):1605-6. View

Dean R, Ferguson D . Effects of disopyramide on the A-V conduction system. Arch Int Pharmacodyn Ther. 1971; 190(1):183-9. View

MOKLER C, VAN ARMAN C . Pharmacology of a new antiarrhythmic agent, gamma-diisopropyl-amino-alpha-phenyl-alpha-(2-pyridyl)-butyramide (SC-7031). J Pharmacol Exp Ther. 1962; 136:114-24. View

Hinderling P, GARRETT E . Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans. J Pharmacokinet Biopharm. 1976; 4(3):199-230. DOI: 10.1007/BF01063614. View

Vismara L, Mason D, Amsterdam E . Disopyramide phosphate: clinical efficacy of a new oral antiarrhythmic drug. Clin Pharmacol Ther. 1974; 16(2):330-5. DOI: 10.1002/cpt1974162330. View

Hartel G, LOUHIJA A, KONTTINEN A . Disopyramide in the prevention of recurrence of atrial fibrillation after electroconversion. Clin Pharmacol Ther. 1974; 15(6):551-5. DOI: 10.1002/cpt1974156551. View

Sekiya A, VAUGHANWILLIAMS E . A COMPARISON OF THE ANTIFIBRILLATORY ACTIONS AND EFFECTS ON INTRACELLULAR CARDIAC POTENTIALS OF PRONETHALOL, DISOPYRAMIDE AND QUINIDINE. Br J Pharmacol Chemother. 1963; 21:473-81. PMC: 1703883. DOI: 10.1111/j.1476-5381.1963.tb02015.x. View

Jensen G, Sigurd B, Uhrenholt A . Haemodynamic effects of intravenous disopyramide in heart failure. Eur J Clin Pharmacol. 1975; 8(3-4):167-73. DOI: 10.1007/BF00567110. View

Befeler B, CASTELLANOS Jr A, Wells D, VAGUEIRO M, Yeh B . Electrophysiologic effects of the antiarrhythmic agent disopyramide phosphate. Am J Cardiol. 1975; 35(2):282-7. DOI: 10.1016/0002-9149(75)90014-4. View

10.

Yeh B, Sung P, Scherlag B . Effects of disopyramide on electrophysiological and mechanical properties of the heart. J Pharm Sci. 1973; 62(12):1924-9. DOI: 10.1002/jps.2600621203. View

11.

WEISSLER A, Harris L, White G . LEFT VENTRICULAR EJECTION TIME INDEX IN MAN. J Appl Physiol. 1963; 18:919-23. DOI: 10.1152/jappl.1963.18.5.919. View

12.

FISCH C, KNOEBEL S, FEIGENBAUM H, GREENSPAN K . Potassium and the monophasic action potential, electrocardiogram, conduction and arrhythmias. Prog Cardiovasc Dis. 1966; 8(5):387-418. DOI: 10.1016/s0033-0620(66)80029-4. View

13.

Kissin M, SCHWARZCHILD M, BAKST H . A nomogram for rate correction of the Q-T interval in the electrocardiogram. Am Heart J. 1948; 35(6):990-2. DOI: 10.1016/0002-8703(48)90598-5. View

14.

WEISSLER A, PEELER R, ROEHLL Jr W . Relationships between left ventricular ejection time, stroke volume, and heart rate in normal individuals and patients with cardiovascular disease. Am Heart J. 1961; 62:367-78. DOI: 10.1016/0002-8703(61)90403-3. View

15.

Turiel S, Smith W . A seminar on Norpace (disopyramide phosphate) a new antiarrhythmic agent. Introductory remarks. Angiology. 1975; 26(1 Pt 2):65-6. View

16.

Katz M, Meyer C, EL-ETR A, SLODKI S . Clinical evaluation of a new anti-arrhythmic agent, SC-7031. Curr Ther Res Clin Exp. 1963; 5:343-50. View

17.

Mason D, SPANN Jr J, Zelis R, Amsterdam E . The clinical pharmacology and therapeutic applications of the antiarrhythmic drugs. Clin Pharmacol Ther. 1970; 11(4):460-80. DOI: 10.1002/cpt1970114460. View